Key result
Selective pharmacological inhibition and silencing of Nav1.6 inhibited myocyte arrhythmic potential and prevented arrhythmias in vivo in mouse models of CPVT.
Why the study?
Does selective inhibition of Nav1.6 prevent arrhythmias in mouse models of CPVT?
Does selective inhibition of Nav1.6 prevent arrhythmias in mouse models of CPVT?
Neuronal Na+ channels, specifically Nav1.6, play a crucial role in beta-adrenergic-mediated arrhythmogenesis in CPVT, highlighting them as a potential antiarrhythmic therapeutic target.
Nav1.6 inhibition merits clinical translation studies in CPVT; hypothesis-generating and should not yet change practice.
Although triggered arrhythmias including catecholaminergic polymorphic ventricular tachycardia (CPVT) are often caused by increased levels of circulating catecholamines, the mechanistic link between β-adrenergic receptor (AR) stimulation and the subcellular/molecular arrhythmogenic trigger(s) is unclear. Here, we systematically investigated the subcellular and molecular consequences of β-AR stimulation in the promotion of catecholamine-induced cardiac arrhythmias. Using mouse models of cardiac calsequestrin-associated CPVT, we demonstrate that a subpopulation of Na+ channels, mainly the neuronal Na+ channels (nNav), colocalize with ryanodine receptor 2 (RyR2) and Na+/Ca2+ exchanger (NCX) and are a part of the β-AR-mediated arrhythmogenic process. Specifically, augmented Na+ entry via nNav in the settings of genetic defects within the RyR2 complex and enhanced sarcoplasmic reticulum (SR) Ca2+-ATPase (SERCA)-mediated SR Ca2+ refill is both an essential and a necessary factor for arrhythmogenesis. Furthermore, we show that augmentation of Na+ entry involves β-AR–mediated activation of CAMKII, subsequently leading to nNav augmentation. Importantly, selective pharmacological inhibition as well as silencing of Nav1.6 inhibit myocyte arrhythmic potential and prevent arrhythmias in vivo. Taken together, these data suggest that the arrhythmogenic alteration in Na+/Ca2+ handling evidenced ruing β-AR stimulation results, at least in part, from enhanced Na+ influx through nNav. Therefore, selective inhibition of these channels and of Nav1.6 in particular can serve as a potential antiarrhythmic therapy.
No takes yet. Share an insight, caveat, or question.
Radwański et al. (2016) studied Catecholaminergic polymorphic ventricular tachycardia (CPVT). Selective pharmacological inhibition and silencing of Nav1.6 was evaluated on Myocyte arrhythmic potential and arrhythmias in vivo. Selective pharmacological inhibition and silencing of Nav1.6 inhibited myocyte arrhythmic potential and prevented arrhythmias in vivo in mouse models of CPVT.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: